

BASICS OF CONTOURING
CONTOURING OF REGIONAL LNS
3 D CT BASED PLANNING OF BCT AND PLAN
EVALUATION

Dr Vineeta Goel
Senior Consultant Radiation Oncology
Max Super Speciality Hospital
New Delhi

Why do we need Contouring?

- RT to breast -reduces local recurrences and is a/w improved survival
- Concern- T/t related morbidity in breast and shoulder
 - Long term risk of heart disease and secondary cancer
- Need to Optimize RT to obtain max effect and minimize morbidity
- Transition from 2D to 3D RT– shift from bony land mark based RT to *individualised* target
- Target volume delineation is the weakest link in quality chain of RT and there are large inter observer variations

Basics are still basics!


- Study Pre operative Clinical findings and diagrams well
 - Location of tumour
 - Size of tumour
 - +/- Tumour involving Nipple areola complex
 - PDO- Present/absent and its extent
 - Axillary/ SC LNs
- Read HPR with due attention

Model HPR Post MRM

- 6x4 cm tumour located in UIQ of Rt Breast
- IDC Grade III
- LVI present
- Deep Margin free and 1.5 cm away from tumour
- Tumour reaching up to Dermis
- Dermal lymphatic emboli present
- DCIS absent
- 4/18 LNs Positive ; largest LN 2.5 cm, ECE Present
- Triple Negative

Basics are still basics!

- Understand your patient's body habitus well
- High BMI- sometimes helps you decide arm position/ elevation
- Check for arm's movement
- If any lymphedema- document it
- Type of Breast-
- Atrophic – careful palpation
- Pendulous breast -identify and try to reduce folds
- Location of tumour- Tumour in Lower quadrant or inner quadrant- need to modify conventional borders



CT Simulation

- Position- Comfortable and reproducible
- Supine
- Breast wedge
- Both arms above head
- IV Contrast Optional (we use IV Contrast only in patients with Positive SCF nodes)

- **Wires-Important Step- Do not hurry!!**
 - Palpate Breast well, look for skin folds, mark with pen both breasts
 - Wire around- I/L Breast
 - Scar
 - Opposite Breast
 - Provisional field borders
- Use copper wires to reduce artefacts
- Free Breathing
- 3- 5 mm scans from neck to L1-2



Pic Courtesy Dr Ashwini Budrukar

Terminology

- Medial, Lateral, Cranial, Caudal, Ventral, Dorsal
- G- Guideline
- MS- My Submission

Normal Anatomy



www.abro-bvro.be





M- Superficial
s in Neck


Manubrium
erni & Medial
avicle



Mastoid process






Scalene Ms – Deep
Neck Ms
D- Transverse
process of C3-6
- First Rib







Major- Thick fan shaped

i) Clavicular head
Sternocostal head-
anterior surface of
manubrium and superior six
costal cartilage
- humerus





Minor- Thin triangular Ms
3-5th Rib
Coracoid process of
scapula







capulae- Large flat



Scapula
3rd or 4th Rib
D7-L5 Vertebrae
Iliac Crest

Humerus







Origin-
 Left CCA- Aortic Arch
 Right CCA- Right Brachiocephalic A



CSA- Aortic arch


CSA- Brachiocephalic Trunk

er Crossing Lateral Border of first rib it
comes axillary A





Axillary A- Three parts medial, posterior and lateral to P Minor Ms


Major veins superior to the heart



Axillary Artery Relations



Axillary V – Drains in Subclavian V



IJV- Unites with Subclavian V to form Brachiocephalic V

Why wires around Breast?

- Large differences are reported b/w CTV localization using standard anatomic borders, palpation and USG
- Hurkmans et al - study in 2001 with palpable breast glandular tissue was marked by lead wire before Planning CT in 6 pts Vs. 4 patients without lead wire
- CTV was delineated by 4 RO
- Deviations in PTV extent were greater in Posterior, Cranial and medial directions
- Interobserver variation in volume was decreased by a factor of 4 on scans with lead wire


IJROBP Vol 50 No5, 2001

RTOG Atlas

- 9 RO from eight institutions independently delineated targets

(Lumpectomy cavity, boost PTV, Breast, SCF, Axillary, IMCLN and chest wall) and OARs (heart and lungs) on same CT images of three representative breast cancer pts

To reduce inconsistencies RTOG proposed a breast cancer atlas



East Cancer Atlas for Radiation
Therapy Planning:
Consensus Definitions



A study at the heart of breast cancer treatment

Breast Contouring
RADCOMP Consortium

v.3

February 23, 2016

Acta Oncologica, 2013; Early Online: 1–8

ORIGINAL ARTICLE

Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: National guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group

info
healthcar

Radiotherapy and Oncology 114 (2015) 3–10

Contents lists available at [ScienceDirect](#)



ELSEVIER

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

ESTRO consensus guidelines

ESTRO consensus guideline on target volume delineation for elective
radiation therapy of early stage breast cancer

Guidelines only Guide!!

- Guidelines serve as base on which CTV can be individually adapted
- Not applicable for T/t in prone position
- **RTOG** – EBC and LABC
- **ESTRO** and **Danish**- EBC
- All Contours are shown- does not mean that all volumes have to be treated


CTV Breast


CTV - Total glandular breast tissues

Cranial- Uppermost level of Palpable/ Visible Breast tissue

Maximally up to inferior edge of sternoclavicular joint (G)

In high BMI patients or patients with large breast, sometimes breast tissue goes above






Caudal- Most Caudal CT slice with visible breast tissue (**G**)

In obese patients, CTV P Breast is positioned more ventrally in the caudal part of breast due to fatty tissue (**G, ESTRO**)


This is actually extension of abdominal wall fat

Helps decreasing dose to heart


- **Dorsal** – Pectoral muscle or intercostal ms where there is no P Major muscle (**G**)




- **RTOG** – to include chest wall also in LABC




Central- 5mm under skin
(G, ESTRO)




ABC with BCS -in cases
with T4b,c,d cancer where
all dose up to skin is
advised (bolus may be
added) (G, ESTRO, RTOG)



- In a thin atrophic breast one may consider keeping skin volumes may be 3mm below skin (MS)
- In superficially located tumours; skin is also a target; one may consider a small patch of bolus around scar (MS)



Superficially Located Tumour




Medial- Clinical Reference / Wire


Maximal to edge of sternum

TV P Breast is positioned lateral to mammary branch of internal

thoracic A (**G, ESTRO**)



- **Lateral-** Most difficult to delineate (varies according to breast ptosis)
 - Mid Axillary Line or 1.5-2 cm beyond palpable breast tissue
(Traditional)
- Medial to lateral thoracic A, Breast fold
(G, ESTRO, DBCG)
- Exclude Lat Dorsi Ms
(RTOG)



Internal Thoracic A is a branch of subclavian A

Lateral Thoracic A is a branch of Axillary A



Words of Caution- Individualization!!

compass primary tumor bed
equately , including relevant margins
ound it



patients with tumours placed too
medially/ laterally one needs to modify
nventional borders

ply wires carefully even on opposite
east as you keep comparing your
ntours with opposite breast





M
S



CTV Chest Wall

- Place radio opaque wires around imaginary- original site of breast and also on MRM scar
- Generally same as breast


CTV Chest Wall

Dorsal-


RTOG guidelines- Rib Pleural interface (including ribs, IC ms and pectoralis ms)

ESTRO- Unless invasion was demonstrated (tumour stage T4 a-c), no reason to routinely include major pectoral muscle and ribs

Impacts Lung and Heart Doses!



Patterns of failure



Most common site of chest wall recurrence from surgical series (72-100%) is **within skin and subcutaneous tissue anterior to pectoralis musculature**

Second MC site is within pectoralis

CTV Thoracic Wall

Ventral-

RTOG- Skin

ESTRO- 5 mm under skin surface


Skin Bolus of 3-5mm may be applied for



very thin CW (ESTRO is only for EBC)

MS -Skin



Inflammatory breast cancer- Up to skin

Bolus for all fractions





M
S



NODAL CONTOURING

Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy – PROCAB guidelines



Karolien Verhoeven^{a,*}, Caroline Weltens^a, Vincent Remouchamps^b, Khalil Mahjoubi^b, Liv Veldeman^c, Benoit Lengele^d, Eszter Hortobagyi^a, Carine Kirkove^d

^a University Hospitals Leuven/KU Leuven; ^b Clinique Sainte Elisabeth (AMPR), Namur; ^c Ghent University Hospital; and ^d Catholic University of Louvain, Brussels, Belgium

National project to improve quality of Breast Radiation Therapy ,
PROCAB (PROject on CANcer of the Breast)

Supra (Infra + Retroclavicular+ Periclavicular) LN



cranial-

TOG -Caudal Edge Cricoid
cartilage

ROCAB -Cranial Edge of
subclavian A Arch


*LABC, up to level of transverse
cervical vessels*

**Lower Border of Cricoid
cartilage (MS)**




Caudal

- **RTOG**-caudal edge of Clavicle
- Junction of Brachiocephalic V and Axillary V
- **MS- Lower border of medial head of Clavicle**



Exclude thyroid and
trachea


Medial Edge of Int carotid
A and IJV



PROCAB



Lateral

- **RTOG**- Cranially- Scalene ms
Caudally- Junction of
first rib and clavicle
- **DBCG**- Medial edge of P Minor
and Clavicle



Ventral

- **Ventral**- SCM, Clavicle, 5 mm below skin
- **Dorsal**- Cranially- Posterior to ICA and Anterior to scalene medius ms
- **Caudally**- Lung






D

B



C

G





M
S



MS

Delineation of Supraclavicular Target Volumes in Breast Cancer Radiation Therapy

Lindsay C. Brown, MD,^{*} Felix E. Diehn, MD,[†]
Audrey C. Boughey, MD,[‡] Stephanie K. Childs, MD,^{*}
Sean S. Park, MD, PhD,^{*} Elizabeth S. Yan, MD,^{*}
Lily A. Petersen, MD,^{*} and Robert W. Mutter, MD^{*}

Departments of ^{}Radiation Oncology, [†]Radiology, and [‡]Surgery, Mayo Clinic, Rochester, Minnesota*




Received Sep 8, 2014, and in revised form Jan 6, 2015. Accepted for publication Feb 12, 2015.

Patterns of SCLNs

- To map location of gross supraclavicular LNs in patients with breast cancer
- 62 patients with 161 SCLNs (at diagnosis or recurrence) were eligible for this study
- Location of SC LNs were mapped on CT/MR/PETCT
- Location of LNs were then transferred on to axial CT scan of a representative patient with both arms abducted in a typical breast RT position
- All LNs were plotted on left side with a circle of diameter 5mm

Distribution of LNs at Diagnosis-


- 35- 40% LNs were outside RTOG SCF Volume
- Location of LNs outside RTOG volumes were
 1. at level of thyroid cartilage- Cranial to RTOG boundaries
 2. Posterolateral to RTOG volumes in posterior triangle
 3. Lateral low SCF below level of transverse cervical vessels and lateral to scalene ms or between anterior and middle scalene muscle.
- No recurrences occurred medial to medial border of ICA




- More generous coverage of SCF in patients with SCLNs at presentation
- Posterior triangle
- Cranial border above cricoid cartilage




PET CT- Laterally and posteriorly located SCLNs—
Posterior Triangle






SCF and Posterior Triangle
Volumes



Indications of Axillary RT



- Not everyone needs it!
- Heavy Axillary burden with ECE
- Soft tissue deposits present in dissected axillary fat
- Inadequate axillary Dissection
- Positive SLN and AC not done

Anatomy of Axilla





Level III Axilla

Medial	P Minor inserts on Coracoid
Medial	Axillary A/V crosses medial edge of P Minor
Medial	Dorsal surface of P Major
Medial	Ribs and IC Ms
Medial	Thoracic Inlet
Medial	Medial border of P Minor





Level II Axilla

Medial	Axillary A/V crosses medial edge of P Minor
Lateral	Axillary A/V crosses lateral edge of P Minor
Anterior	Anterior surface of P minor
Posterior	Ribs and IC Ms
Medial	Medial border of P Minor
Lateral	Lateral border of P Minor




Level I Axilla

Proximal	Axillary A crosses lateral edge of P Minor
Distal	P major inserts into ribs
Central	Plane defined by anterior surface of P major and Lat Dorsi
Superficial	Subscapularis
Lateral	Lateral border of P Minor
Medial	Medial border of Lat Dorsi



Interpectoral LNs


Anterior	Axillary A crosses medial edge of P Minor
Caudal	Caudal border of P Minor
Dorsal	Dorsal surface of P major
Ventral	Ventral surface of P Minor
Medial	Medial border of P Minor
Lateral	Lateral border of P Major



ESTRO



I/C of IMC LN

- Presence Of IMC LNs
- Central or Medial Quadrant tumour with Heavy axillary LN positivity



Internal Mammary LNs

Cranial	Junction of SCV and Juglar V/ cranial aspect of 1 st Rib (and Caudal border of SCF)
Caudal	Cranial aspect of 4 th Rib
Medial	Cranially- Manubrium Sterni Caudally- Dorsal surface of IC Ms
Dorsal	5 mm space dorsal of IM Vessels, not beyond pleura
Medial	5 mm space medial of IM Vessels
Lateral	5 mm space lateral of IM Vessels



OARS


- Heart- Contoured below pulmonary trunk bifurcation
- Coronaries
- All mediastinal tissue below this level should be contoured including great vessels
- I/L and C/L Lungs
- Opposite Breast
- Head of Humerus

- Plan Generation
- 3 DCRT
- Forward IMRT- Field in Field
- Hybrid IMRT




Set user origin

Join medial and lateral markers



Slide Courtesy Dr Ashwini Budrukar




Lateral tangent

Field ID	Technique	Machine/Energy	MLC	Field Weight	Scale	Gantry Rtn [deg]	Coll Rtn [deg]	Couch Rtn [deg]	Wedge	Field X [cm]	[cm]	Field Y [cm]	[cm]	[cm]	X [cm]	Y [cm]	Z [cm]
Field 1	STATIC-I	Equinox-80 - 1X		1.00	IEC61217	231.4	0.0	0.0	None	11.0	-6.5	+5.5	20.0	-10.0	+10.0	-13.3	-9.7

CF13406

- C1
 - Plan1
 - Plan2
 - Plan3
 - Practise_plan
 - Plan_practise
- Plan_practise
 - CT_1
 - Registered Images
 - CT_1
 - BODY
 - None
 - SCF
 - User Origin
 - Reference Points
 - None
 - Dose
 - Fields
 - Field 1
 - Field 1-DRR
 - Field 2
 - Field 2-DRR



Group	Field ID	Technique	Machine/Energy	MLC	Field Weight	Scale	Gantry Rtn [deg]	Coll Rtn [deg]	Couch Rtn [deg]	Wedge	Field X [cm]	[cm]	Field Y [cm]	[cm]	[cm]	X [cm]	Y [cm]	Z [cm]
✓	Field 1	STATIC-I	Equinox-80 - 1X		1.00	IEC61217	233.3	5.0	0.0	None	11.0	-6.5	+5.5	20.0	-10.0	+10.0	-11.1	-9.9
✓	Field 2	STATIC-I	Equinox-80 - 1X		1.00	IEC61217	61.1	365.0	0.0	None	11.0	-6.5	+5.5	20.0	-10.0	+10.0	-11.1	-9.9

Slide Courtesy Dr Ashwini Budrukar




COBALT -2 field, no wedge

Slide Courtesy Dr Ashwini Budrukar


BAD PLANS COBALT with WEDGE





Slide Courtesy Dr Ashwini Budrukar



6 MV, 2-field
showing dose
inhomogeneity
superiorly and
inferiorly



Slide Courtesy
Ashwini
Budrukar








6 MV photons with 15 degree wedge in lateral tangent

Forward IMRT

Field-in-field technique:


- Medial and lateral tangents are first planned and dose distribution noted.
- Areas of high dose are then contoured/delineated.
- A new field is created within the existing tangential field with an appropriate MLC configuration so as to reduce the inhomogeneity in these areas.
- These fields are finally fused by the treatment planning system.

Forward Planned IMRT



Multiple subfields in each tangent

All the subfields merged to form dynamic MLC motion



Hybrid IMRT

- Add Bilateral open Tangential fields
- Add Bilateral IMRT Tangential Fields to reduce dose inhomogeneity and reduce high doses to ipsilateral lung and heart

DVH

- Evaluate both CTV and PTV –

PTV	Ideal	Acceptable
D95%	95%	
D90%		90%
Dmax	< 115%	<120%

OAR Doses

C/L Breast D max	<3Gy
I/L Lung V 20Gy	<15 -20%
I/L Lung V 10Gy	<35 -40%
I/L Lung V 5Gy	<50 -55%
C/L Lung V5 Gy	<10% -15%
Heart (Left Breast Cancer) V20Gy	<10%
Heart (Left Breast Cancer) V10Gy	<30%
Heart (Right Breast Cancer) V20Gy	0%
Heart (Right Breast Cancer) V10Gy	<10 -15%
Mean	<4 -5Gy

OAR Doses -HF

	CF	HF
/L Lung	V 20Gy	V 16Gy
	V 10 Gy	V 8 Gy
	V 5Gy	V 4Gy
Heart	V 25Gy	V 20 Gy
	V 20Gy	V 16Gy

THANKS